Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 26;47:170–183. doi: 10.1016/j.ebiom.2019.08.035

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Published by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 5 — High-grade hOEC cell proliferation after MF, P4, PGRMC1 inhibitor and TGFβ1 treatment.

Effects of MF (a) or P4 (b) treatment on the proliferation HG-hOEC cells. Cell proliferation of the treated groups is presented as the percentage of the control (considered as 100%). Immunohistochemical staining of PGR in LG-hOEC (c) and HG-hOEC (d) and PGRMC1 in LG-hOEC (e) and HG-hOEC (f). Effects of MF and P4 treatments with or without the AG-205 inhibitor on HG-hOEC cell proliferation (g). Cell proliferation of the treated groups is presented as the percentage of the control (considered as 100%). Effects of MF and P4 treatments with or without the AG-205 inhibitor on HG-hOEC cell invasion (h). Cell invasion of the treated groups is presented as the percentage of the control (considered as 100%). TGFβ1 levels in C, MF-treated and P4-treated hOEC explants with or without AG-205 inhibitor (i). qPCR analysis of TGFB1 expression levels in the control, MF-treated or P4-treated hOEC explants with or without the AG-205 inhibitor (j). Each bar represents the mean ± SEM relative to PPIA. Asterisks indicate significant differences between non-treated control and treated groups (*, P < .05; **, P < .01; ***, P < .001; ****, P < .0001) (One-way ANOVA with the post-hoc Bonferroni's test). Original magnification, 40×; scale bar, 50 μm. AG-205, PGRMC1 inhibitor; C, control; HG, high-grade; hOEC, human ovarian epithelial cancer; LG, low-grade; MF, mifepristone; P4, progesterone.